Michael May
Michael May is the President and CEO of CCRM. Michael completed his BASc in Chemical Engineering at the University of Toronto in 1991. He then went on to complete his PhD in Chemical Engineering at the University of Toronto under the supervision of Michael Sefton in 1998. From 2000-2010, Michael was the President, Chief Operating Officer and Co-founder of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity. Michael sits on a number of Boards and advisory committees and he has coached hockey at the Rep level for over seven years.
Posts by: Michael
10 days ago in Toronto….
The 10-year boom of the cell and gene therapy (CGT) industry has inevitably come to an end: public CGT valuations are way down, companies are settling into cash conservation mode, unrealistic salary demands are being replaced by layoffs, and the vultures circling with $billions in their coffers are patiently waiting for “the feeding frenzy.” Alas, […]
Thinking about longevity makes me feel old
In pondering David Sinclair’s statement “Aging is far more reversible than we thought,” I couldn’t help but reflect on how much our field has changed since I was in grad school. Alas, looking back that far makes me feel really old! My PhD in cell encapsulation focused on diabetes using porcine islets conformally coated in […]
“It was the best of times, it was the worst of times….”
It is difficult to imagine how many times the opening lines to Charles Dickens’ classic A Tale of Two Cities, written over 160 years ago, has been used to describe the world’s current state of affairs. Yet, I am challenged to identify any other time during my lifetime, and most of my parents’, when the […]
Why I helped build CCRM: A journey from inspiration to impact
Fifteen years ago, regenerative medicine in Canada stood at an inflection point. The science was world-class, the academic talent was undeniable, and the promise of cell and gene therapies was beginning to capture global attention. Yet there was a critical problem: too many discoveries were trapped in laboratories, unable to navigate the long and complex […]